Real-world treatment patterns and clinical outcomes of HCV treatment-naive patients in China: an interim analysis from the CCgenos study.
OBJECTIVE
In China, chronic hepatitis C virus (HCV) infection represents a considerable healthcare burden. Although interferon-based therapy has been the standard-of-care for many years, few long-term, real-life studies have assessed interferon-based treatment in China. The objective of CCgenos follow-up study was to analyze long-term treatment patterns and outcomes in a cohort of treatment-naïve, Han ethnic, patients with chronic HCV infection.


METHODS
Patients who had participated in the CCgenos cross-sectional study were invited to enter this 5-year follow up. Clinical information and centralized HCV-RNA measures were collected at scheduled study visits every 6 months for untreated patients and every 3 months for treated patients.


RESULTS
Among 512 patients enrolled, 334 (65.2%) received interferon-based treatment and 178 (34.8%) remained untreated over a median of 4.1 (1.2-4.3) years. A total of 82.8% (424/512) of patients had an IL28B CC genotype (GT); 60.7% (311/512) had HCV GT1b infection, including 121 (38.9%) untreated. Most patients with baseline cirrhosis were untreated (26/46, 56.5%). Among patients who completed treatment and 24 weeks of post-treatment follow up, the duration of interferon-based therapy was frequently longer than recommended (52.9% [92/174] of GT1b-infected were treated for > 1 year). Rates of sustained virologic response (SVR24) were 71.1% (226/318) overall; 62.4% (111/178) among patients with HCV GT1b infection; and 42.9% (15/35) among patients with cirrhosis.


CONCLUSIONS
There remains a high unmet need for effective HCV treatment in China, evidenced by a high proportion of patients remaining untreated by the current standard-of-care and relatively low SVR24 rates for patients with both GT1b infection and cirrhosis.
Peking University Hepatology Institute, Beijing Key Laboratory for Hepatitis C and Immunotherapy for Liver Disease, Peking University People's Hospital, Beijing.
Hui-Ying
HY
Rao
Bristol-Myers Squibb, Wallingford.
Hong
H
Li
The First Hospital of Lanzhou University, Lanzhou.
Hong
H
Chen
Henan Provincial People's Hospital, Zhengzhou.
Jia
J
Shang
Shanghai Ruijin Hospital, Jiaotong University School of Medicine, Shanghai.
Qing
Q
Xie
The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou.
Zhi-Liang
ZL
Gao
The First Affiliated Hospital of Nanjing Medical University, Nanjing.
Jun
J
Li
Tangdu Hospital, Xi'an.
Yongtao
Y
Sun
The First Affiliated Hospital of Guangxi Medical University, Nanning.
Jianning
J
Jiang
The Second Hospital of Shandong University, Jinan.
Lei
L
Wang
The First Affiliated Hospital of Shanxi Medical University, Taiyuan.
Longfeng
L
Zhao
The First Affiliated Hospital of Nanchang University, Nanchang.
Lunli
L
Zhang
The First Affiliated Hospital of Kunming Medical University, Kunming.
Weibo
W
Yang
The First Hospital of Jilin University, Changchun.
Junqi
J
Niu
Renmin Hospital of Wuhan University, Wuhan.
Zuojiong
Z
Gong
The Second Xiangya Hospital of Central South University, Changsha.
Guozhong
G
Gong
Peking University Hepatology Institute, Beijing Key Laboratory for Hepatitis C and Immunotherapy for Liver Disease, Peking University People's Hospital, Beijing.
Ruifeng
R
Yang
Institute of Clinical Medicine, National Yang-Ming University, Taipei.
Mei-Hsuan
MH
Lee
Peking University Hepatology Institute, Beijing Key Laboratory for Hepatitis C and Immunotherapy for Liver Disease, Peking University People's Hospital, Beijing.
Lai
L
Wei
D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000097:blood; D002681:China / Q000453:epidemiology; D015331:Cohort Studies; D003430:Cross-Sectional Studies; D005260:Female; D005500:Follow-Up Studies; D016174:Hepacivirus / Q000235:genetics; D019698:Hepatitis C, Chronic / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology / Q000821:virology; D006801:Humans; D007372:Interferons / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D012367:RNA, Viral / Q000097:blood; D013997:Time Factors; D016896:Treatment Outcome
D015415:Biomarkers; D012367:RNA, Viral; D007372:Interferons
HCV; SVR; cirrhosis; genotype 1b; treatment pattern